Zoetis Inc. (NYSE:ZTS) Shares Sold by Certuity LLC

Certuity LLC lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 88.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,386 shares of the company’s stock after selling 11,131 shares during the quarter. Certuity LLC’s holdings in Zoetis were worth $226,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Mizuho Securities USA LLC grew its position in shares of Zoetis by 13,726.9% in the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after purchasing an additional 4,829,815 shares during the period. International Assets Investment Management LLC lifted its position in Zoetis by 41,235.7% during the third quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock worth $183,652,000 after buying an additional 937,700 shares during the period. Assenagon Asset Management S.A. grew its holdings in Zoetis by 296.9% in the 4th quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company’s stock valued at $144,917,000 after buying an additional 665,331 shares during the period. Nordea Investment Management AB increased its stake in shares of Zoetis by 38.3% during the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock valued at $336,266,000 after acquiring an additional 572,511 shares during the last quarter. Finally, Holocene Advisors LP acquired a new position in shares of Zoetis during the 3rd quarter valued at about $110,809,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. UBS Group started coverage on shares of Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. Stifel Nicolaus dropped their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Piper Sandler lowered their price target on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday. Finally, Morgan Stanley cut their price objective on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $214.00.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $165.28 on Friday. The business’s 50-day simple moving average is $169.08 and its 200 day simple moving average is $179.08. The company has a market cap of $74.57 billion, a P/E ratio of 31.07, a PEG ratio of 2.77 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. On average, sell-side analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.21%. Zoetis’s dividend payout ratio is presently 37.59%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.